Quick filters:
Open Data
Open Code
Pre-registered
Funding Declared
COI Declared
Open Access
Clear Filters
How I manage anemia related to myelofibrosis and its treatment regimens.
Ann Hematol
(Unknown)
Published: 2023
Improved benefit of continuing luspatercept therapy: sub-analysis of patients with lower-risk MDS in the MEDALIST study.
Germing U; Fenaux P; Platzbecker U; Buckstein R; Santini V; Díez-Campelo M; Yucel A; Tang D; Fabre S; Zhang G; Zoffoli R; Ha X; Miteva D; Hughes C; Komrokji RS; Zeidan AM; Garcia-Manero G.
Ann Hematol
(Unknown)
Published: 2023
Fludarabine plus reduced-intensity busulfan versus fludarabine plus myeloablative busulfan in patients with non-Hodgkin…
Kamijo K; Shimomura Y; Shinohara A; Mizuno S; Kanaya M; Usui Y; Kim SW; Ara T; Mizuno I; Kuriyama T; Nakazawa H; Matsuoka KI; Kusumoto S; Maseki N; Yamaguchi M; Ashida T; Onizuka M; Fukuda T; Atsuta Y; Kondo E.
Ann Hematol
(Unknown)
Published: 2023
Whole-exome sequencing identifies FANC heterozygous germline mutation as an adverse factor for immunosuppressive therap…
Shen Y; Liu Q; Li H; Liu W; Hu H; Zhao Y; Li Y; Chen Y; Liu S; Yu Q; Zhuang H; Wu L; Hu Z; Zheng Z; Shen J; Lin S; Shen Y; Zhou Y; Ye B; Wu D.
Ann Hematol
(Unknown)
Published: 2023
Molecular response patterns in relapsed/refractory AML patients treated with selinexor and chemotherapy.
Klement P; Fiedler W; Gabdoulline R; Dallmann LK; Wienecke CP; Schiller J; Kandziora C; Teich K; Heida B; Büttner K; Brandes M; Funke C; Wichmann M; Othman B; Chromik J; Amberg S; Kebenko M; Schlipfenbacher V; Wilke AC; Modemann F; Janning M; Serve H; Bokemeyer C; Theile S; Deppermann U; Kranich AL; Ganser A; Thol F; Heuser M.
Ann Hematol
(Unknown)
Published: 2022
Multidisciplinary tumor board analysis: validation study of a central tool in tumor centers.
Frank B; Ihorst G; Herget G; Schäfer H; Neubauer J; Calba MA; Textor D; Möller MD; Wenger S; Jung J; Waldschmidt J; Miething C; Rassner M; Greil C; Wäsch R; Engelhardt M.
Ann Hematol
(Unknown)
Published: 2022
Philadelphia-negative chronic myeloproliferative neoplasm follow-up: when the phone rings. Changes during the COVID-19 …
Ortuzar A; Fox ML; Vera JA; Lorenzo Vizcaya Á; Marín Sánchez A; Llopis Calatayud I; Carbonell S; Álvarez-Larrán A; Mata Serna R; Marco Buades JE; Quiroz Cervantes K; Martínez Hellín Á; Blum Domínguez A; Caballero Navarro G; Cáceres Sansaloni A; Guerrero Fernández L; Muñoz Linares C; Gasior Kabat M; Pérez López R; Fernández Rodríguez Á; Martínez Bilbao C; Cobo Rodríguez MT; Díaz Á; Durán MA; Santaliestra Tomas M; García-Gutierrez V; Magro Mazo E; Hernández-Boluda JC; Segura A; Raya JM; Navas Elorza B; Osorio S.
Ann Hematol
(Unknown)
Published: 2022
Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: a…
Dal MS; Ulu BU; Uzay A; Akay OM; Beşışık S; Yenerel MN; Çelik S; Kaynar L; Yücel OK; Deveci B; Sönmez M; Mehtap Ö; Beköz HS; Sunu C; Salim O; Ulaş T; Kartı S; Altuntaş F; Ferhanoğlu B; Tuğlular TF.
Ann Hematol
(Unknown)
Published: 2022
Characteristics and outcomes of patients undergoing high-dose chemotherapy and autologous stem cell transplantation adm…
Garcia Borrega J; Böll B; Kochanek M; Naendrup JH; Simon F; Sieg N; Hallek M; Borchmann P; Holtick U; Shimabukuro-Vornhagen A; Eichenauer DA; Heger JM.
Ann Hematol
(Unknown)
Published: 2022
Ibrutinib in mantle cell lymphoma: a real-world retrospective multi-center analysis of 77 patients treated in the Czech…
Obr A; Benesova K; Janikova A; Mocikova H; Belada D; Hruskova A; Vockova P; Salek D; Sykorova A; Furst T; Malarikova D; Papajik T; Trneny M; Klener P.
Ann Hematol
(Unknown)
Published: 2022
Clonogenic assays improve determination of variant allele frequency of driver mutations in myeloproliferative neoplasms.
Kalmer M; Pannen K; Lemanzyk R; Wirths C; Baumeister J; Maurer A; Kricheldorf K; Schifflers J; Gezer D; Isfort S; Brümmendorf TH; Koschmieder S; Chatain N.
Ann Hematol
(Unknown)
Published: 2022